Rose Marie Cazzani, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 45 E Bel Air Rd, Cranston, RI 02920 Phone: 401-392-0564 Fax: 401-435-4231 |
Ashley Leja, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 51 Sockanosset Cross Rd, Cranston, RI 02920 Phone: 401-944-7574 |
Jessie Andoscia, Physical Medicine & Rehabilitation - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 1700 Cranston St, Cranston, RI 02920 Phone: 401-223-0230 |
Natasha Sepe, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1700 Cranston St, Cranston, RI 02920 Phone: 401-232-0230 |
Blanki Cherubini, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1150 Reservoir Ave Ste 303, Cranston, RI 02920 Phone: 401-401-0159 |
Amanda Lee Zarriello, DPT Physical Medicine & Rehabilitation - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Worthington Rd, Cranston, RI 02920 Phone: 401-338-1713 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs.
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.
"There will be an opportunity for the public to provide input on breast implants and no regulatory decisions have been made at this point. My officials have been looking at several models over the last few weeks to determine how best to receive public input," the Minister said.
Indian researchers report the development of a novel, simple screening tool with a high degree of accuracy for the detection of oral premalignancies that can be used in a general health setting without the need for much training or clinical experience.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
› Verified 9 days ago